India  

FDA authorizes Pfizer's Covid-19 vaccine for children 5 to 11

Video Credit: Bleacher Report AOL - Duration: 02:49s - Published
FDA authorizes Pfizer's Covid-19 vaccine for children 5 to 11CNN’s Nick Watt reports.

You Might Like


💡 newsR Knowledge: Other News Mentions

Food and Drug Administration Food and Drug Administration Agency of the US Department of Health and Human Services

CDC Signs Off on COVID Vaccine Boosters for Kids Ages 5–11 [Video]

CDC Signs Off on COVID Vaccine Boosters for Kids Ages 5–11

CDC Signs Off on COVID Vaccine Boosters , for Kids Ages 5–11. CNN reports that on May 19, the CDC's Advisory Committee on Immunization Practices (ACIP)... . ... voted in support of recommending an additional Pfizer shot for 5- to 11-year-olds who've received their first two doses. The vote was 11-1 with 1 abstention. CNN reports that the FDA authorized the booster dose earlier this week. Children within this age group are advised to wait at least five months after receiving their two-dose regimen before getting a booster shot. CNN reports a fourth dose is recommended for children who are immunocompromised. . According to Pfizer, a trial of 4,500 children ages 5-11 showed Omicron-fighting antibodies were 36 times stronger upon receiving a booster. The company also says no new safety issues were detected. On May 16, the American Academy of Pediatrics reported that COVID cases in U.S. children rose 76% the previous week compared to two weeks prior. CDC Director Dr. Rochelle Walensky gave opening remarks before the ACIP's vote. The sadness I feel for lives lost, the families devastated and the communities changed is steep. We have the tools we need to protect these people from severe disease and prevent any more tragic deaths, Dr. Rochelle Walensky, via opening remarks before the ACIP's vote, via CNN

Credit: Wibbitz Top Stories    Duration: 01:31Published
Biden Invokes Defense Powers to Address Baby Formula Shortage [Video]

Biden Invokes Defense Powers to Address Baby Formula Shortage

Biden Invokes Defense Powers , to Address Baby Formula Shortage. President Joe Biden invoked the Defense Production Act on May 18. “Operation Fly Formula” will make use of planes owned by the Defense Department to assist in the distribution of baby formula. The planes will be deployed both nationally and internationally. I know parents all across the country are worried about finding enough infant formula to feed their babies — , President Joe Biden, via 'The New York Times'. ... as a parent and as a grandparent, I know just how stressful that is, President Joe Biden, via 'The New York Times'. [I have directed my administration] to do everything possible to ensure there’s enough safe baby formula.., President Joe Biden, via 'The New York Times'. ... and that it’s quickly reaching families that need it the most, President Joe Biden, via 'The New York Times'. In this case, the Defense Production Act allows the president to order companies to prioritize the production and distribution of baby formula. . The House of Representatives approved $28 million in emergency funds to address the shortage. It also approved a bill that would ease restrictions on the types of formula that can be purchased through federal aid programs geared toward women and children. I know what it means to not be able to stretch out milk for the entire month, Rep. Jahana Hayes, (CA-D), via 'The New York Times'. With everything going on right now, the last thing a family should have to worry about is feeding their children, Rep. Jahana Hayes, (CA-D), via 'The New York Times'. This is so basic. Everyone understands that we’re all on high alert here, and this is an incredible emergency, Sen. Debbie Stabenow, (MI-D), via 'The New York Times'. While the emergency funds did not receive overwhelming bipartisan support, the bill to ease baby formula purchasing restrictions did. The emergency funds would allow the U.S. Food and Drug Administration to increase its ability to oversee companies that produce baby formula. Both measures are expected to pass in the Senate

Credit: Wibbitz Top Stories    Duration: 01:31Published
Biden Admin Opens Up Another Round of Free At-Home COVID Tests Delivered by USPS [Video]

Biden Admin Opens Up Another Round of Free At-Home COVID Tests Delivered by USPS

Biden Admin Opens Up Another Round , of Free At-Home COVID Tests , Delivered by USPS. The White House announced the new round of available tests on May 17. The Biden administration has made up to 16 free at-home COVID tests available to American households. The Biden administration has made up to 16 free at-home COVID tests available to American households. Providing the tests makes good on one of President Joe Biden's pledges during the initial Omicron wave in the U.S. The tests have been approved by the U.S. Food and Drug Administration (FDA) and deliver results in 15 minutes. The process of ordering them has been simplified, and the tests arrive in the mail via USPS. To date, nearly 350 million of the at-home COVID tests have been ordered and delivered. COVID cases have risen dramatically in recent weeks. On May 16, more than 95,000 new cases of COVID were reported in the U.S. COVID hospitalizations have also risen by 26 percent in the past two weeks. The tests have become an important resource in early detection of the virus. Going to a large gathering? , Dr. Ashish K. Jha, White House COVID Response Coordinator, via 'The New York Times'. Use rapid tests to not be the person who brings COVID to the party, Dr. Ashish K. Jha, White House COVID Response Coordinator, via 'The New York Times'. Visiting a vulnerable relative? , Dr. Ashish K. Jha, White House COVID Response Coordinator, via 'The New York Times'. Use rapids tests to keep them safe, Dr. Ashish K. Jha, White House COVID Response Coordinator, via 'The New York Times'. Those who wish to order the at-home tests should visit covidtests.gov

Credit: Wibbitz Top Stories    Duration: 01:31Published
Pfizer’s COVID Booster Shot for 5 to 11 Year Olds Authorized by FDA [Video]

Pfizer’s COVID Booster Shot for 5 to 11 Year Olds Authorized by FDA

Pfizer’s COVID Booster Shot , for 5 to 11 Year Olds, Authorized by FDA. NBC News reports on May 17, the Food and Drug Administration (FDA)... … announced it had authorized Pfizer-BioNTech's coronavirus booster dose for 5 to 11 year olds. The FDA says eligible recipients of a booster dose could receive the extra shot starting five months after their initial two-dose series. Per NBC News, Pfizer's booster shot for 5 to 11 year olds is 10 micrograms ... . ... a third of the dosage given to citizens 12 and older. Following the FDA's ruling, it is now up to the Centers for Disease Control and Prevention (CDC) to recommend how to implement boosters for the age group. CDC data shows less than one third of 5 to 11 year olds in the United States have recieved the primary series of a COVID-19 vaccine. Experts say booster shots offer better protection against the omicron strain and its associated subvariants. The CDC's Advisory Committee on Immunization Practices will reportedly discuss booster shots on May 19. Dr. Rochelle Walensky, the Director of the CDC, should have her final recommendation following the committee's discussion

Credit: Wibbitz Top Stories    Duration: 01:30Published
Increased Number of COVID-19 Deaths Among Vaccinated Americans [Video]

Increased Number of COVID-19 Deaths Among Vaccinated Americans

Increased Number of COVID-19 Deaths , Among Vaccinated Americans. CNN reports as COVID-19 vaccines became available, there has been a stark divide in deaths between those who received a vaccine and those who did not. . But experts say as vaccine protection has diminished, . more transmissible variants have made coronavirus deaths closer to an even split. In recent months, breakthrough infections have heightened risks for vulnerable populations. According to federal data, less than 25% of deaths occurred in vaccinated citizens during the peak of the Delta Variant. Comparatively, vaccinated Americans accounted for over 40% of deaths at the height of Omicron. Experts say those who have only received the first series of coronavirus vaccines may be three times more likely to die. Almost no one in this country should be dying from Covid. , Dr. Robert Califf, commissioner US FDA, via CNN. What we really should be worried about is getting the boosters that we need to stay up to date so with the new variants that we have... , Dr. Robert Califf, commissioner US FDA, via CNN. ...we don’t have unnecessary deaths and hospitalizations. , Dr. Robert Califf, commissioner US FDA, via CNN

Credit: Wibbitz Top Stories    Duration: 01:30Published

Pfizer Pfizer American multinational pharmaceutical corporation

Pfizer's First Quarter Profits Blast Past 2022 Forecast [Video]

Pfizer's First Quarter Profits Blast Past 2022 Forecast

Pfizer's First Quarter , Profits Blast Past, 2022 Forecast. ABC reports that Pfizer's COVID-19 vaccine and treatment sales helped propel the pharmaceuticals company beyond Wall Street's first quarter expectations. . Pfizer's coronavirus vaccine Comirnaty raked in over $13 billion in sales for the first quarter. . Pfizer's coronavirus vaccine Comirnaty raked in over $13 billion in sales for the first quarter. . The vaccine has remained Pfizer's top selling product for almost the last year. . The drugmaker's pill treatment Paxloid reportedly added an additional $1.5 billion to the company's sales. . ABC reports that Pfizer's, profits grew 61% , in the first quarter. . On May 3, the company posted a net income of $7.86 billion and first quarter adjusted earnings of $1.62 per share. . The results easily exceeded the $1.49 increase predicted by industry analysts. . Compared to the same time last year, the company's revenue skyrocketed 77% , to reach $25.66 billion. . According to ABC, the drugmaker expects the company's total revenue in 2022 to reach between $98 billion and $102 billion. . Pfizer's COVID vaccine launched late in 2020 and quickly became the company's top selling product by the second quarter of 2021. In December of 2021, Pfizer's stock reached an all-time high of $61.71 per share.

Credit: Wibbitz Top Stories    Duration: 01:31Published
Biden Administration Secures 20 Million Courses of Paxlovid [Video]

Biden Administration Secures 20 Million Courses of Paxlovid

Biden Administration Secures , 20 Million Courses of Paxlovid. Biden Administration Secures , 20 Million Courses of Paxlovid. CNN reports that on April 25, a senior administration official said , 20 million treatment courses of Pfizer's antiviral COVID pill have been secured for the United States to purchase. 100,000 treatment courses will be provided to pharmacies per quarter as need and uptake are observed. . A treatment course of Paxlovid consists of taking three pills twice a day for five days. CNN reports that Pfizer released data last year showing that its antiviral COVID pill reduced the risk of hospitalization or death by 89% if taken within a few day of exhibiting symptoms. Paxlovid first became authorized by the FDA at the end of December. And there were very, very few pills around. The administration worked incredibly hard to both increase production and acquisition, and the good news is we’ve made really substantial progress, Dr. Ashish Jha, White House COVID-19 Response Coordinator, to NPR. Now we’ve got to turn those pills into prescriptions and into the things that patients can get so that they can get better if they get infected. We have a big set of efforts that we have been working on and launching, and we’re going to be doing a lot more this week, Dr. Ashish Jha, White House COVID-19 Response Coordinator, to NPR. On April 26, the administration is expected to announce expanded access to the pills via its federal antiviral pharmacy program. It is estimated that over 30,000 locations may provide free treatments in the future through the test-to-treat initiative. While the purchase of a significant amount of treatment courses has been secured thus far. CNN reports that the administration "will not be able to purchase more" unless it secures further funding from Congress

Credit: Wibbitz Top Stories    Duration: 01:30Published
Moderna Working on Vaccine Booster That Targets the Omicron Variant [Video]

Moderna Working on Vaccine Booster That Targets the Omicron Variant

Moderna Working on , Vaccine Booster That Targets, the Omicron Variant. The Associated Press reports that Moderna is developing an updated COVID-19 booster that offers protection against the omicron variant. On April 19, the pharmaceutical company released data suggesting that work on the updated booster was making progress. Prior to the emergence of omicron, Moderna had been developing a booster with added protection against the beta variant of coronavirus. According to the company, people who received that specific booster produced more antibodies capable of fighting a number of variants. AP reports that the omicron variant is able to more easily slip past the immune system's defenses than the original coronavirus. According to health officials, distributing boosters every few months does not present a practical solution to the mutating virus. As a result, Moderna and its rival Pfizer are testing "bivalent" shots which mixes each company's original vaccine with an updated omicron version. . As a result, Moderna and its rival Pfizer are testing "bivalent" shots which mixes each company's original vaccine with an updated omicron version. . Moderna's bivalent shot reportedly includes 32 variant mutations of the coronavirus. Studies on the new bivalent shots are currently underway in the United States and Britain. . Results from the studies are expected by late June

Credit: Wibbitz Top Stories    Duration: 01:30Published

COVID-19 COVID-19 Contagious disease caused by SARS-CoV-2

Nicola Sturgeon tests positive for COVID

Nicola Sturgeon has tested positive for coronavirus.
Sky News

Two rare Omicron types reclassified as COVID variants of concern in UK

Two rare types of Omicron have been reclassified as COVID variants of concern in the UK.
Sky News

Covid 4th wave: Delhi reports 530 new cases, positivity rate more than 2%

The capital had on Thursday logged 520 Covid cases with a positivity rate of 2.09 per cent and one death due to the disease.
DNA

Centre calls for intensive 'mission mode' push to Covid vaccination across country

Underlining the urgent need for an intensive 'mission mode' push to COVID-19 vaccination across the country to accelerate the recent placid momentum, the Centre..
IndiaTimes

Related news from verified sources

FDA nod to Pfizer's low-dose COVID-19 vaccine for children aged 5-11 years in US

It is expected that the FDA will soon give its formal green signal to Pfizer, making 28 million young...
DNA - Published


Related videos from verified sources

FDA issues emergency use authorization for Pfizer vaccine in children 5 to 11 [Video]

FDA issues emergency use authorization for Pfizer vaccine in children 5 to 11

FDA issues EUA for Pfizer vaccine in kids 5 to 11

Credit: WEWS NewsChannel5     Duration: 02:55Published
The American Academy of Pediatrics welcomes FDA's decision to authorize Pfizer's Covid-19 vaccine for children 5 to 11 [Video]

The American Academy of Pediatrics welcomes FDA's decision to authorize Pfizer's Covid-19 vaccine for children 5 to 11

Dr. Lee Savio Beers discusses with CNN’s Jake Tapper.

Credit: Bleacher Report AOL     Duration: 04:18Published
FDA Authorizes Pfizer’s COVID-19 Vaccine for Kids Ages 5 to 11 [Video]

FDA Authorizes Pfizer’s COVID-19 Vaccine for Kids Ages 5 to 11

FDA Authorizes , Pfizer’s COVID-19 Vaccine, for Kids Ages 5 to 11. On October 29, the Food and Drug Administration gave authorization for Pfizer-BioNTech's COVID-19 vaccine for children ages 5 to..

Credit: Wibbitz Top Stories     Duration: 01:30Published